News
For the most recent news and press releases, visit our investor relations website: www.ir.icecure-medical.com
IceCure to Present at the H.C. Wainwright Global Life Sciences Conference
CAESAREA, Israel, March 3, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that destroys tumors
IceCure Medical summarizes the achievements of 2020 and addresses a letter to shareholders
Caesarea March 1, 2021 – IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that ablates tumors by
IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East
Three-Year Agreement Launches Distribution of IceCure’s ProSense® Cryoablation System in the United Arab Emirates and Arabian Gulf States CAESAREA, Israel, February 17, 2021 — IceCure Medical
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS MARCH 7th, 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Monday, March 7, 2021
IceCure Announces a $15 Million Private Placement and Intention to Pursue NASDAQ Listing
Upon closing, the company to meet Nasdaq listing requirements without the need to effect a concurrent public offering; funds to enable the company to expand
IceCure Inks Expanded Distribution Agreement with Terumo Corporation for Thailand
Expanded Agreement Builds from the Success of its Current Joint Activities in Japan and Singapore, to Bring its Cryoablation Products to Benefit More Patients in
IceCure to Present at the H.C. Wainwright Global Life Sciences Conference
CAESAREA, Israel, March 3, 2021 — IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that destroys tumors
IceCure Medical summarizes the achievements of 2020 and addresses a letter to shareholders
Caesarea March 1, 2021 – IceCure Medical Ltd. (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation cryoablation technology that ablates tumors by
IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East
Three-Year Agreement Launches Distribution of IceCure’s ProSense® Cryoablation System in the United Arab Emirates and Arabian Gulf States CAESAREA, Israel, February 17, 2021 — IceCure Medical
ICECURE GIVES NOTICE OF SPECIAL GENERAL MEETING FOR COMPANY SHAREHOLDERS MARCH 7th, 2021
Notice is hereby given of the convening of a special general meeting for the shareholders of IceCure to be held on Monday, March 7, 2021
IceCure Announces a $15 Million Private Placement and Intention to Pursue NASDAQ Listing
Upon closing, the company to meet Nasdaq listing requirements without the need to effect a concurrent public offering; funds to enable the company to expand
IceCure Inks Expanded Distribution Agreement with Terumo Corporation for Thailand
Expanded Agreement Builds from the Success of its Current Joint Activities in Japan and Singapore, to Bring its Cryoablation Products to Benefit More Patients in